ESR1 and breast carcinoma: Importantly, retrospective Kaplan–Meier analysis and ROC analysis showed that high HDAC2 and survivin, and low miR-125a-5p, expression levels significantly correlate with poor overall or relapse-free survival in tamoxifen or endocrine therapy-treated ER+ breast cancer patients.